Not finding it? Sign in to also search OpenAlex live.
-
Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study
Maurice J. D. L. van der Vorst, Constanza Maximiano Alonso, Tirza Areli Calderón Boyle, Jeanne M. Schilder, Izabela A. Malinowska, Guilan Ye, +8 more
0citations -
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer2021 Journal of Translational Medicine article Medicine PARP inhibition in cancer therapy Open access cited by 1 patent
Jinyu Meng, Jin Peng, Jie Feng, Jochen Maurer, Xiao Li, Yan Li, +11 more
63citations -
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Maria De Santis, Sara Martínez Breijo, Paul J. Robinson, Camille Capone, Katie C Pascoe, Suzy Van Sanden, +6 more
10citations -
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer
Guilhem Roubaud, Gerhardt Attard, Martin Boegemann, David Olmos, Marco Trevisan, Laurent Antoni, +6 more
4citations -
Real-World Risk Of MDS/AML And Other Secondary Primary Malignancies In Patients With Epithelial Ovarian Cancer Treated With Niraparib Maintenance Therapy: Final Results From A Regulatory Safety Study2025 International Journal of Gynecological Cancer article Medicine Multiple and Secondary Primary Cancers Open access
Constanza Maximiano Alonso, Maurice Van Der Vorst, Tirza Areli Calderón Boyle, Jeanne M. Schilder, Izabela A. Malinowska, Guilan Ye, +6 more
0citations -
ENGOT-ov62 - reducing chemotherapy duration in high-grade advanced ovarian cancer: A comparison of 3 vs. 6 cycles of platinum-based chemotherapy followed by niraparib maintenance in HRD-positive patients2026 International Journal of Gynecological Cancer article Medicine Ovarian cancer diagnosis and treatment Open access
Jalid Sehouli, Eva Roser, Robert Armbrust, Dario Zocholl, Jessica Nguyen, Jessika Goldmann, +10 more
0citations -
469 Survey on the usage of PARP-inhibitor therapy in Germany – a national NOGGO/JAGO-AGO intergroup study2021 International Journal of Gynecological Cancer article Medicine PARP inhibition in cancer therapy Open access
Bich Doan Nguyen-Sträuli, P Meyer-Wilmes, Joanna Baum, A Kreklau, Christina Buschmann, S Boz, +6 more
0citations
8 results